Benicar Related Published Studies
Well-designed clinical trials related to Benicar (Olmesartan)
Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. [2009.08.01]
Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). [2009.07]
Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. [2009.02]
Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. [2009.02]
Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. [2009.01]
Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. [2009]
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. [2009]
Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods. [2008.12.20]
Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. [2008.07]
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. [2008]
Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. [2007.12]
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. [2007.03]
Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. [2007]
Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. [2006.09]
Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. [2006.09]
Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients. [2006.07]
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. [2006.06]
Prevention of migraine with olmesartan in patients with hypertension/prehypertension. [2006.03]
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. [2006.02]
A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. [2006]
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. [2006]
Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. [2006]
Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. [2005.01]
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. [2005]
Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. [2004.08]
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. [2004.03]
Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. [2004.03]
Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. [2003.06]
Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. [2003]
A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? [2002.11]
Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. [2002.09]
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. [2001.09]
Well-designed clinical trials possibly related to Benicar (Olmesartan)
Estimating Antihypertensive Effects of Combination Therapy in an Observational Study Using Marginal Structural Models. [2009.10.13]
Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs: A Systematic Review and Meta-Analysis. [2009]
Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. [2007.08]
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. [2007.01]
Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. [2006.04]
The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. [2006.03]
The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. [2006.01.05]
Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. [2005.11]
Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. [2005.04]
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. [2005.04]
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. [2004.08.31]
The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. [2002.10]
Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. [2001.05]
Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. [1997.12]
Other research related to Benicar (Olmesartan)
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. [2009.10.09]
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. [2009.08]
Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. [2009.05]
Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. [2009.03]
Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. [2009]
Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy : a randomized, double-blind, parallel-group, multicentre study. [2009]
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. [2009]
Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. [2009]
Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. [2009]
Olmesartan medoxomil/amlodipine. [2009]
Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil. [2009]
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. [2008.12]
Early antihypertensive efficacy of olmesartan medoxomil. [2008.12]
Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. [2008.11]
Based treatment algorithm for essencial hypertension with olmesartan medoxomil. [2008.09]
Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. [2008.07.07]
Olmesartan for the treatment of arterial hypertension. [2008.07]
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. [2008.04]
The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan. [2008.04]
Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. [2008.03]
Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. [2008.01]
Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus. [2008.01]
Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension. [2008.01]
Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. [2008.01]
Possible beneficial effect of olmesartan medoxomil on left atrial function in patients with hypertension : noninvasive assessment by acoustic quantification. [2008]
Olmesartan medoxomil: a review of its use in the management of hypertension. [2008]
Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. [2008]
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. [2008]
Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. [2007.12]
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. [2007.12]
Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. [2007.11]
Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. [2007.10]
Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. [2007.10]
Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. [2007.09.18]
Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. [2007.09]
An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy. [2007.09]
[Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension] [2007.05.19]
Effect of olmesartan on oxidative stress in hemodialysis patients. [2007.05]
Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. [2007.04]
Olmesartan medoxomil-induced angioedema. [2007.03]
Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. [2007.03]
[Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus] [2007.03]
Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension. [2007]
Efficacy and Tolerability of Olmesartan Medoxomil in Patients with Mild to Moderate Essential Hypertension : The OLMEBEST Study. [2007]
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. [2007]
Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. [2006.10]
[Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension] [2006.10]
Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. [2006.03]
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. [2006]
Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence. [2006]
Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study. [2006]
The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. [2006]
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. [2006]
Olmesartan medoxomil: current status of its use in monotherapy. [2006]
Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. [2005.12.28]
|
